Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin H. van Vliet is active.

Publication


Featured researches published by Martin H. van Vliet.


Thrombosis and Haemostasis | 2004

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Loes E. Visser; Ron H.N. van Schaik; Martin H. van Vliet; Paul H. Trienekens; Peter A. G. M. De Smet; Arnold G. Vulto; Albert Hofman; Cornelia M. van Duijn; Bruno H. Stricker

The principal enzyme involved in coumarin metabolism is CYP2C9. Allelic variants of CYP2C9, CYP2C9*2 and CYP2C9*3, code for enzymes with reduced activity. Despite increasing evidence that patients with these genetic variants require lower maintenance doses of anticoagulant therapy, there is lack of agreement among studies on the risk of bleeding and CYP2C9 polymorphisms. It was, therefore, our objective to study the effect of the CYP2C9 polymorphisms on bleeding complications during initiation and maintenance phases of coumarin anticoagulant therapy. The design of the study was a population-based cohort in a sample of the Rotterdam Study, a study in 7,983 subjects. All patients who started treatment with acenocoumarol or phenprocoumon in the study period from January 1, 1991 through December 31, 1998 and for whom INR data were available were included. Patients were followed until a bleeding complication, the end of their treatment, death or end of the study period. Proportional hazards regression analysis was used to estimate the risk of a bleeding complication in relation to CYP2C9 genotype after adjustment for several potentially confounding factors such as age, gender, target INR level, INR, time between INR measurements, and aspirin use. The effect of variant genotype on bleeding risk was separately examined during the initiation phase of 90 days after starting therapy with coumarins. The 996 patients with analysable data had a mean follow-up time of 481 days (1.3 years); 311 (31.2%) had at least 1 variant CYP2C9 allele and 685 (68.8%) had the wild type genotype. For patients with the wild type genotype, the rate of minor bleeding, major bleeding and fatal bleeding was 15.9, 3.4 and 0.2 per 100 treatment-years, respectively. For patients with a variant genotype, the rate of minor, major and fatal bleeding was 14.6, 5.4 and 0.5 per 100 treatment-years. Patients with a variant genotype on acenocoumarol had a significantly increased risk for a major bleeding event (HR 1.83, 95% CI: 1.01-3.32). During the initiation phase of therapy we found no effect of variant genotype on bleeding risk. In this study among outpatients of an anticoagulation clinic using acenocoumarol or phenprocoumon, having a variant allele of CYP2C9 was associated with an increased risk of major bleeding events in patients on acenocoumarol, but not in patients on phenprocoumon. Although one might consider the assessment of the CYP2C9 genotype of a patient for dose adjustment before starting treatment with acenocoumarol, a prospective randomised trial should demonstrate whether this reduces the increased risk of major bleeding events.


Pharmacogenetics | 2004

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Loes E. Visser; Martin H. van Vliet; Ron H.N. van Schaik; A. A. Kasbergen; Peter A. G. M. De Smet; Arnold G. Vulto; Albert Hofman; Cornelia M. van Duijn; Bruno H. Stricker

Cytochrome P4502C9 (CYP2C9) is the main enzyme implicated in coumarin anticoagulant metabolism. The variant alleles CYP2C9*2 and CYP2C9*3 are associated with an increased response to warfarin. However, an effect on acenocoumarol dose requirements appears to be absent for the CYP2C9*2 allele and the consequences for the metabolism of phenprocoumon have not yet been established. We investigated CYP2C9 polymorphisms in relation to the international normalized ratio (INR) during the first 6 weeks of treatment and its effect on the maintenance dose in a cohort of 1124 patients from the Rotterdam Study who were treated with acenocoumarol or phenprocoumon. There was a statistically significant difference in first INR between patients with variant genotypes and those with the wild-type. Almost all acenocoumarol-treated patients with a variant genotype had a significantly higher mean INR and had a higher risk of an INR > or = 6.0 during the first 6 weeks of treatment. A clear genotype-dose relationship was found for acenocoumarol-treated patients. For patients on phenprocoumon, no significant differences were found between variant genotypes and the wild-type genotype. Individuals with one or more CYP2C9*2 or CYP2C9*3 allele(s) require a significantly lower dose of acenocoumarol compared to wild-type patients. Phenprocoumon appears to be a clinically useful alternative in patients carrying the CYP2C9*2 and *3 alleles.


Clinical Pharmacology & Therapeutics | 2005

Allelic Variants of Cytochrome P450 2C9 Modify the Interaction Between Nonsteroidal Anti‐inflammatory Drugs and Coumarin Anticoagulants

Loes E. Visser; Ron H.N. van Schaik; Martin H. van Vliet; Paul H. Trienekens; Peter A. G. M. De Smet; Arnold G. Vulto; Albert Hofman; Cornelia M. van Duijn; Bruno H. Stricker

Cytochrome P450 (CYP) plays a key role in the metabolism of coumarin anticoagulants and nonsteroidal anti‐inflammatory drugs (NSAIDs). Because CYP2C9 is a genetically polymorphic enzyme, genetic variability could play an important role in the potential interaction between NSAIDs and coumarins. We investigated whether NSAIDs were associated with overanticoagulation during therapy with coumarins and evaluated the effect of the CYP2C9 polymorphisms on this potential interaction.


Pharmacogenomics | 2011

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

Ron H.N. van Schaik; Marleen Kok; Fred C.G.J. Sweep; Martin H. van Vliet; Marianne van Fessem; Marion E. Meijer-van Gelder; Caroline Seynaeve; Jan Lindemans; Jelle Wesseling; Laura J. van 't Veer; Paul N. Span; Hanneke W. M. van Laarhoven; Stefan Sleijfer; John A. Foekens; Sabine C. Linn; Els M. J. J. Berns

AIMS Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients. MATERIALS & METHODS A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced disease patients treated with first-line tamoxifen were genotyped for CYP2C19*2 and *17 variant alleles, with primary end point time-to-treatment failure (TTF). Effects of CYP2C19, independent of treatment, were analyzed in 243 primary systematic untreated patients. RESULTS CYP2C19*2 hetero- and homozygote patients combined showed significantly longer TTFs (hazard ratio [HR]: 0.72; 95% CI: 0.57-0.90; p = 0.004). In multivariate analysis, including CYP2D6*4 status, CYP2C19*2 remained independently associated with TTF (HR: 0.73; 95% CI: 0.58-0.91; p = 0.007). In untreated patients, the CYP2C19*17 allele was significantly associated with a longer disease-free interval (HR: 0.66; 95%CI: 0.46-0.95; p = 0.025). CONCLUSION CYP2C19 genotyping is potentially important for tamoxifen therapy for advanced disease and for breast cancer prognosis.


Blood | 2015

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Rowan Kuiper; Martin H. van Vliet; Annemiek Broijl; Bronno van der Holt; Laila el Jarari; Erik H. van Beers; George Mulligan; Hervé Avet-Loiseau; Walter Gregory; Gareth J. Morgan; Hartmut Goldschmidt; Henk M. Lokhorst; Pieter Sonneveld

Patients with multiple myeloma have variable survival and require reliable prognostic and predictive scoring systems. Currently, clinical and biological risk markers are used independently. Here, International Staging System (ISS), fluorescence in situ hybridization (FISH) markers, and gene expression (GEP) classifiers were combined to identify novel risk classifications in a discovery/validation setting. We used the datasets of the Dutch-Belgium Hemato-Oncology Group and German-speaking Myeloma Multicenter Group (HO65/GMMG-HD4), University of Arkansas for Medical Sciences-TT2 (UAMS-TT2), UAMS-TT3, Medical Research Council-IX, Assessment of Proteasome Inhibition for Extending Remissions, and Intergroupe Francophone du Myelome (IFM-G) (total number of patients: 4750). Twenty risk markers were evaluated, including t(4;14) and deletion of 17p (FISH), EMC92, and UAMS70 (GEP classifiers), and ISS. The novel risk classifications demonstrated that ISS is a valuable partner to GEP classifiers and FISH. Ranking all novel and existing risk classifications showed that the EMC92-ISS combination is the strongest predictor for overall survival, resulting in a 4-group risk classification. The median survival was 24 months for the highest risk group, 47 and 61 months for the intermediate risk groups, and the median was not reached after 96 months for the lowest risk group. The EMC92-ISS classification is a novel prognostic tool, based on biological and clinical parameters, which is superior to current markers and offers a robust, clinically relevant 4-group model.


Genetic Testing and Molecular Biomarkers | 2013

Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays

Martin H. van Vliet; Belinda Dumee; Erik Simons; Lars Bullinger; Konstanze Döhner; Hartmut Döhner; Henk Viëtor; Bob Löwenberg; Erik H. van Beers

Mutations in the gene encoding nucleophosmin (NPM1) carry a prognostic value for patients with acute myeloid leukemia (AML). Various techniques are currently being used to detect these mutations in routine molecular diagnostics. Incorporation of accurate NPM1 mutation detection on a gene expression platform would enable simultaneous detection with various other expression biomarkers. Here we present an array-based mutation detection using custom probes for NPM1 WT mRNA and NPM1 type A, B, and D mutant mRNA. This method was 100% accurate on a training cohort of 505 newly diagnosed unselected AML cases. Validation on an independent cohort of 143 normal-karyotype AML cases revealed no false-negative results, and one false positive (sensitivity 100.0% and specificity 98.7%). Based on this, we conclude that this method provides a reliable method for NPM1 mutation detection. The method can be applied to other genes/mutations as long as the mutant alleles are sufficiently highly expressed.


Experimental hematology & oncology | 2013

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC.

Jaap Brand; Martin H. van Vliet; Leonie de Best; Peter J. M. Valk; Henk Viëtor; Bob Löwenberg; Erik H. van Beers

High levels of BAALC, ERG, EVI1 and MN1 expression have been associated with shorter overall survival in AML but standardized and clinically validated assays are lacking. We have therefore developed and optimized an assay for standardized detection of these prognostic genes for patients with intermediate cytogenetic risk AML. In a training set of 147 intermediate cytogenetic risk cases we performed cross validations at 5 percentile steps of expression level and observed a bimodal significance profile for BAALC expression level and unimodal significance profiles for ERG and MN1 levels with no statistically significant cutoff points near the median expression level of BAALC, ERG or MN1. Of the possible cutoff points for expression levels of BAALC, ERG and MN1, just the 30th and 75th percentile of BAALC expression level and the 30th percentile of MN1 expression level cutoff points showed clinical significance. Of these only the 30th percentile of BAALC expression level reproduced in an independent verification (extended training) data set of 242 cytogenetically normal AML cases and successfully validated in an external cohort of 215 intermediate cytogenetic risk AML cases. Finally, we show independent prognostic value for high EVI1 and low BAALC in multivariate analysis with other clinically relevant molecular AML markers. We have developed a highly standardized molecular assay for the independent gene expression markers EVI1 and BAALC.


Genetic Testing and Molecular Biomarkers | 2013

Detection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array

Martin H. van Vliet; Pia Burgmer; Linda de Quartel; Jaap Brand; Leonie de Best; Henk Viëtor; Bob Löwenberg; Erik H. van Beers

Double (bi-allelic) mutations in the gene encoding the CCAAT/enhancer-binding protein-alpha (CEBPA) transcription factor have a favorable prognostic impact in acute myeloid leukemia (AML). Double mutations in CEBPA can be detected using various techniques, but it is a notoriously difficult gene to sequence due to its high GC-content. Here we developed a two-step gene expression classifier for accurate and standardized detection of CEBPA double mutations. The key feature of the two-step classifier is that it explicitly removes cases with low CEBPA expression, thereby excluding CEBPA hypermethylated cases that have similar gene expression profiles as a CEBPA double mutant, which would result in false-positive predictions. In the second step, we have developed a 55 gene signature to identity the true CEBPA double-mutation cases. This two-step classifier was tested on a cohort of 505 unselected AML cases, including 26 CEBPA double mutants, 12 CEBPA single mutants, and seven CEBPA promoter hypermethylated cases, on which its performance was estimated by a double-loop cross-validation protocol. The two-step classifier achieves a sensitivity of 96.2% (95% confidence interval [CI] 81.1 to 99.3) and specificity of 100.0% (95% CI 99.2 to 100.0). There are no false-positive detections. This two-step CEBPA double-mutation classifier has been incorporated on a microarray platform that can simultaneously detect other relevant molecular biomarkers, which allows for a standardized comprehensive diagnostic assay. In conclusion, gene expression profiling provides a reliable method for CEBPA double-mutation detection in patients with AML for clinical use.


Clinical Lymphoma, Myeloma & Leukemia | 2017

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

Erik H. van Beers; Martin H. van Vliet; Rowan Kuiper; Leonie de Best; Kenneth C. Anderson; Ajai Chari; Sundar Jagannath; Andrzej J. Jakubowiak; Shaji Kumar; Joan Levy; Daniel Auclair; Sagar Lonial; Donna E. Reece; Paul G. Richardson; David Siegel; A. Keith Stewart; Suzanne Trudel; Ravi Vij; Todd M. Zimmerman; Rafael Fonseca

&NA; An independent dataset of 91 multiple myeloma patients were tested with eight prognostic mRNA expression signatures. SKY92 best predicted survival (HR = 8.2) and classified the largest fraction (21%) as high risk. Finally 38/91 (42%) cases were low risk by the recently proposed combination SKY92 + ISS achieving a HR 10 for low versus high risk. Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity. Patients and Methods: Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients. Results: The classifiers identified between 9%‐21% of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2. Conclusion: Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10.


Pharmacogenomics | 2018

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe

Jennifer G. Gaultney; Therese W Ng; Carin A. Uyl-de Groot; Pieter Sonneveld; Erik H. van Beers; Martin H. van Vliet; William K. Redekop

Biomarkers associated with prognosis in multiple myeloma (MM) can be used to stratify patients into risk categories. An attractive alternative to uniform treatment (UT), risk-stratified treatment (RST) is proposed where high-risk patients receive bortezomib-based regimens while standard-risk patients receive alternative less costly regimens. An early Markov-type decision analytic model evaluated the potential therapeutic and economic value of different RST strategies compared with UT in MM patients in key European countries. Results suggest RST strategies were both cheaper and more effective than UT across all countries, with the molecular marker-only strategy RST-SKY92 producing maximum health gains (0.031-0.039 QALYs). The conclusions remained consistent in the univariate sensitivity analyses. These findings should encourage stakeholders to support the adoption of RST approaches in MM.

Collaboration


Dive into the Martin H. van Vliet's collaboration.

Top Co-Authors

Avatar

Erik H. van Beers

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Pieter Sonneveld

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Rowan Kuiper

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Belinda Dumee

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Bob Löwenberg

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Bronno van der Holt

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Ron H.N. van Schaik

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Annemiek Broijl

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

George Mulligan

Millennium Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge